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Abstract
This systematic review and meta-analysis was performed to investigate the possible changes of FGF-19 and FGF-21 after
bariatric surgery (BS). Electronic databases including PubMed and Scopus were systematically searched up to February 2020
to identify pertinent studies. A total of 25 different studies were included. The overall pooled analysis identified that BS caused a
significant increase in FGF-19, but had no significant effect on FGF-21. For FGF-19, this finding was supported in the subgroup
analyses. For FGF-21, Roux-en-Y gastric bypass (RYGB) surgery significantly increased FGF-21 levels, whereas, in studies
with follow-up duration ≥ 1 year, FGF-21 levels decreased significantly. BS reduces circulating concentration of FGF-19, but
might increase FGF-21 after RYGB or decrease FGF-21 after ≥ 1 year.
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Introduction
The prevalence of obesity has increased dramatically over the
past decades worldwide representing a main threat for public
health [1]. Obesity is accompanied by many metabolic compli-
cations such as endocrine dysregulations, insulin resistance,
dyslipidemia, cardiovascular disease, nonalcoholic fatty liver
disease, and subclinical inflammation resulting in a rise in mor-
bidity and mortality [2]. Unfortunately, traditional approaches,
such as diets and exercise, have not been so effective for the
long-term management of weight, particularly in severe obese
patients [3]. Bariatric surgery (BS) is presently the most
effective therapeutic approach for severe obesity, yielding an
improvement in its comorbidities, such as type 2 diabetes [2].
In addition to classical pathogenic factors, fibroblast growth
factor 19 (FGF-19), the human ortholog of FGF-15 in the
mouse, and FGF-21 are novel metabolically active hormones
that have been intensively investigated given their therapeutic
potential in obesity and metabolic recovery following BS, par-
ticularly for diabetes [4]. FGF-19 is produced primarily in
enterocytes of distal ileum [5], while FGF-21 is secreted pre-
dominantly in the liver with lower secretion rates in the muscle,
adipose tissue, and pancreas [6]. Both FGF-19 and FGF-21 are
metabolic regulators of adiposity, energy homeostasis, and lipid
and glucose metabolism [7, 8]. FGF-19 plays a crucial role in
controlling bile acids [9]; decreasing food intake and brain-
hedonistic responses [10]; and increasing fatty acid oxidation,
insulin sensitivity, and energy expenditure [11]. Moreover, it
has been shown that exogenous administration of FGF-19 or its
overexpression reduces body weight and may have hypolipid-
emic and antidiabetic impacts [12, 13]. On the other side, FGF-
21 is a powerful stimulator of glucose uptake and lipolysis in
adipose tissue [14] with strong anti-steatosis [15], anti-inflam-
matory, antidiabetic, and hypolipidemic effects [16]. FGF-21
also plays a role in dietary macronutrient selection and regulat-
ing sweet taste preference [17, 18]. Accordingly, understanding
changes in these hormones after surgery-induced weight loss
has an important clinical value.
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Previous studies investigating the impact of the potential
effect of weight loss caused by BS on circulating concentra-
tions of FGF-19 and FGF-21 have reported inconclusive re-
sults, and this area of research is in debate. While several
studies revealed significant favorable effects of BS on these
hormones [16, 19, 20], other studies did not identify a signif-
icant effect [20, 21]. The disagreement among the literatures
may be resulted from differences in the follow-up duration,
surgery type, or baseline weight. Therefore, this systematic
review and meta-analysis was performed to summarize the
findings of previous studies and quantify the potential effect
of BS on FGF-19 and FGF-21 levels based on the follow-up
duration, baseline body mass index, and surgery type.
Methods
This meta-analysis was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) Statement relevant to health care [22].
Search Strategy
The main databases, including PubMed and Scopus, were sys-
tematically searched on 20 February 2020 without any lan-
guage restriction. The databases were searched using the fol-
lowing search strategy to find pertinent articles:
(((((((((((((((“Bariatric Surgery”[Majr]) OR “Bariatric
Surgery”[Title/Abstract]) OR “Gastric Bypass”[Title/
Abstract ] ) OR Gastrectomy[Ti t le /Abst ract ] ) OR
“Bil iopancreat ic Diversion” [Ti t le /Abstract] ) OR
Gastroplasty[Title/Abstract]) OR bariatric[Title/Abstract]) OR
Roux-en-Y[Title/Abstract]) OR RYGB[Title/Abstract]) OR
“Sleeve gastrectomy”[Title/Abstract]) OR “Gastric
sleeve”[Title/Abstract]) OR “gastric band*”[Title/Abstract])
OR Lap-Band[Title/Abstract]) OR “duodenal switch”[Title/
Abstract])) AND ((((((((((“Fibroblast Growth Factors”[Mesh])
OR “fibroblast growth factors”) OR “fibroblast growth factor”)
OR FGF) OR “fibroblast growth factor-19”) OR FGF-19) OR
“fibroblast growth factor-21”) OR FGF-21) OR “fibroblast
Growth Factor-23”) OR FGF-23). Moreover, the reference lists
of all included studies and pertinent reviews were manually
scanned for additional relevant studies.
Inclusion and Exclusion Criteria
In the current meta-analysis, prospective non-randomized co-
hort studies and randomized clinical trials investigating the
impacts of BS on fasting concentrations of FGF-19 and
FGF-21 published up to February 2020 were included.
Studies were included if (1) reported prospectively fasting
concentrations of FGF-19 or FGF-21 pre-surgery and
postsurgery, (2) the sample size was 8 or more, (3) the
follow-up duration was at least 1 month, and (3) reported the
study outcomes as mean ± standard deviation (SD) or suffi-
cient information to calculate them. Studies were excluded if
(1) assessed postprandial levels of outcomes after a meal in-
gestion; (2) assessed outcomes following a lifestyle weight
loss program; (3) study duration was less than 1 month; (4)
were case control or cross-sectional in design; (5) studies were
reviews, animal or in vitro studies, editorials, and case reports.
Besides, the studies by Kaválková et al. [23] and Nierop et al.
[24], which assessed the effect of duodenal–jejunal bypass
liner (DJBL) device implantation on FGF-19, were excluded
because this technique is not a kind of BS. The titles/abstracts
of all included publications were screened for assessing eligi-
bility by the corresponding author (SH) and another investi-
gator (AH) to check for consistency, after which each re-
viewer’s included studies were compared and the measure of
agreement was calculated using kappa statistic. Inter-rater
agreement for selecting the studies for full-text review was
excellent with a kappa score of 0.89, showing a high correla-
tion between the two authors.
Data Extraction
With the use of a standardized data collection form, the fol-
lowing information was collected from each study: the first
author’s name, year of publication, country, background dis-
ease, patients’ age and gender, sample size, type of BS,
follow-up duration, and the mean ± SD of BMI, FGF-21
(pg/ml), and FGF-19 (pg/ml) before and after the BS. For
some studies, data had been reported on figures; for these
studies, data was extracted using the Plot Digitizer software.
Data extraction was conducted independently by two investi-
gators (AH and SH), and disagreements concerning data ex-
traction were resolved by discussion until consensus reached.
Statistical Analysis
Since most included studies presented data as pg/ml, where
data was presented as ng/ml or ng/dl, these were converted to
pg/ml prior to analysis. Where data was reported as mean±
standard error (SE), SE was converted to SD using the follow-
ing formula: SD = SE × √n (n = sample size in each group).
When data was reported as median ± interquartile range
(IQR), assuming normal distribution of data, median was con-
sidered as mean, and SD was calculated as IQR/1.35. When
endpoint means + SDs had not been reported but net changes
from baseline (after–before) were reported, we calculated end-
point means as “net change + baseline mean” and SD was
calculated with the use of the following formula using a cor-
relation coefficient of 0.5 [25]: SD (difference) = [(SD2 (inter-
vention) + SD2 (control) − 2 × 0.5 × SD (intervention) × SD
(control)]1/2. Pooled effect sizes in this meta-analysis were
presented as weighted mean differences (WMD) and 95%
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CI for outcomes. The heterogeneity across the studies was
tested using I2 statistic and was considered significant if
p < 0.1 [26]. Because of the significant heterogeneity, the
random-effects model was used to compare final values and
baseline values of outcomes following BS. Moreover, sub-
group analyses (by study duration, study population, baseline
BMI) and meta-regression analyses (based on baseline BMI
and follow-up period) were applied to find the sources of
heterogeneity. The presence of publication bias was evaluated
by Egger test and funnel plot [27]. Moreover, the overall qual-
ity of the evidence in each pooled analysis was evaluated with
the use of the Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) [28]. Meta-analysis
was conducted by STATA software (version 13.0; StataCorp,
College Station, TX, USA).
Results
Study Characteristics
The initial systematic search of databases found 275 studies.
Of which, after removing 46 duplicate articles, 185 were ex-
cluded after scanning the titles/abstracts because they were
irrelevant to the present meta-analysis. After carefully screen-
ing of 44 full texts, we also excluded 19 more studies because
they assessed postprandial levels of outcomes after a meal test,
used a lifestyle weight loss program, used duodenal–jejunal
bypass liner device implantation, the duration was less than
1 month, or were case control studies in design, animal or
in vitro studies, and reviews. Ultimately, a total of 25 different
studies [9, 20, 29–51] with a total of 886 participants, pub-
lished between 2011 and 2019, were eligible for the meta-
analysis. The flow chart of study selection is presented in
Fig. 1. Data obtained included 19 studies with 27 data sets
on FGF-19 [9, 16, 19–21, 29–42] and 10 studies with 14 data
sets on FGF-21 [6, 16, 34, 35, 40, 43–47]. The majority of the
studies recruited obese patients without comorbidities [6, 16,
20, 31, 34–38, 43–45], while 4 studies reported their result for
patients with type 2 diabetes mellitus (T2DM) diabetic and
participants without T2DM separately (for these studies, we
considered each study as 2 data sets) [21, 32, 40, 42], 7 studies
were just performed on patients with T2DM [9, 19, 29, 30, 33,
39, 41], and 2 studies were on participants without T2DM [46,
47]. The sample size of the analyzed studies ranged between 8
and 115 participants. The follow-up duration of studies ranged
from 1 to 24 months. The baseline BMI of participants ranged
from 33.4 to 60.6. Patients underwent Roux-en-Y gastric by-
pass (RYGB) in 8 studies [9, 21, 30, 32, 35, 42, 44, 46] and
sleeve gastrectomy (SG) in 8 studies [16, 19, 20, 31, 36, 38,
41, 45], while 4 studies reported their results for RYGB and
SG separately [29, 34, 39, 47], and 1 study reported its result
for RYGB and laparoscopic adjustable gastric banding
(LAGB) separately [40]; for these studies, we considered each
study as 2 data sets. The remaining procedures were duodenal
diverted SG with ileal interposition (DDSG-II) [33], LAGB
[37], laparoscopic greater curvature plication (LGCP) [43],
and various surgery types [6]. Additionally, the sex of partic-
ipants was not reported in 4 studies [35, 45–47], 1 article just
included men [19], 3 articles just included women [16, 30,
40], and other ones involved both sexes. The characteristics
of all included studies are presented in Table 1.
Findings from Meta-Analysis
Bariatric Surgery and FGF-19
Among the included studies examining FGF-19 as an out-
come, BMI decreased significantly by − 10.68 kg/m2 follow-
ing BS (Supplemental Fig. 1). Pooled effect size from 27 data
sets, stratified by surgery type, overall revealed that the FGF-
19 circulating levels increased significantly by 46.14 pg/ml
following BS (WMD= 46.14, 95% CI 35.01 to 57.26; p =
˂ 0.001), with a significant heterogeneity across studies
(I2 = 75.8%, p ˂ 0.001). Both RYGB (WMD= 39.09, 95%
CI 20.66–57.53) and SG (WMD = 62.55, 95% CI 46.07–
79.03) significantly increased serum levels FGF-19; however,
SG had a more potent effect on FGF-19 than RYGB (Fig. 2).
In the subgroup analysis by follow-up duration (Supplemental
Fig. 2 and Table 2), baseline BMI (Supplemental Fig. 3 and
Table 2), sex of participants (Supplemental Fig. 4 and
Table 2), and background disease (Supplemental Fig. 5 and
Table 2), the mentioned increase in FGF-19 was observed too,
except in obesity with other comorbidities but not T2DM,
females, and patients undergoing other miscellaneous types
of BS (n = 4 studies), which FGF-19 did not change signifi-
cantly (Table 2).
Bariatric Surgery and FGF-21
In the studies that investigated changes in FGF-21 levels after
BS, BMI decreased significantly by − 12.37 kg/m2 following
BS (Supplemental Fig. 6). Overall, when all data were pooled,
BS had no significant effect on the serum levels of FGF-
21(WMD= 70.80, 95% CI − 20.30 to 161.89; p = 0.12) and
a significant evidence for heterogeneity was observed (I2 =
90.30%, p ˂ 0.001) (Fig. 3). Nevertheless, in the subgroup
analysis by follow-up duration (Supplemental Fig. 7 and
Table 2), baseline BMI (Supplemental Fig. 8 and Table 2),
sex of participants (Supplemental Fig. 9 and Table 2), and
background disease (Supplemental Fig. 10 and Table 2), it
was found that RYGB is significantly related to increased
FGF-21 levels (WMD= 188.84, 95% CI 6.85 to 370.83; p =
0.04), whereas, in studies with follow-up duration ≥ 1 year,
FGF-21 levels decreased significantly following BS (WMD=
− 41.27, 95% C − 70.74 to − 11.81; p = 0.006). Based on the
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meta-regression analysis, follow-up time after BS was in-
versely related to FGF-21 levels in patients undergoing
RYGB (β: − 78.96; SE: 13.26, p = 0.004) so that, by increas-
ing time from surgery, the serum concentration of FGF-21
decreased. No significant effect in this regard was identified
in other subgroups (Table 2).
Meta-Regression
Meta-regression analysis revealed that the levels of FGF-19
(β: 3.15; SE: 1.30, p = 0.02; Fig. 4a) and FGF-21 (β: − 22.40;
SE: 10.60, p = 0.05; Fig. 4b) were modified by the follow-up
time. Changes in FGF-19 (Supplemental Fig. 11) and FGF-
21(Supplemental Fig. 12) were not affected by baseline BMI.
Publication Bias and Evaluation of Quality of Evidence
According to the GRADE
There was no significant evidence of publication bias for stud-
ies examining the impact of BS on FGF-19 (Fig. 5a) and FGF-
21 (Fig. 5b) based on Egger’s linear regression test and by
visual inspection of funnel plots. Using the GRADE system,
the quality of the evidence across studies was classified as
moderate for FGF-19, but the quality of the evidence was
low for FGF-21 (Table 3).
Discussion
The present meta-analysis of available studies revealed that
BS reduces serum levels of FGF-19, but might increase
FGF-21 after RYGB or decrease FGF-21 after ≥ 1 year fol-
low-up. Moreover, meta-regression analyses indicated that
changes in FGF-19 and FGF-21 are affected by follow-up
duration.
In addition to inconsistent findings of studies exploring the
effect of BS on serum levels of FGF-19 and FGF-21, weight
loss interventions using energy-restricted diets also have re-
ported inconclusive results in this regard [34, 48, 49]. Mai
et al. [49] identified that moderate weight loss (~ 5 kg) follow-
ing a hypocaloric diet and physical activity for 6 months did
not change FGF-21 concentrations in obese individuals.
Moreover, Lips et al. [48] showed that a very low calorie diet
is significantly related to an elevation in FGF-21 levels in
obese patients with diabetes 3 weeks and 3 months after in-
tervention. In another study [6], weight and adiposity decrease
by an energy-restricted diet decreased serum levels of FGF-
21, and weight recovery represented a tendency to raise FGF-
21 or at least lessen its decrease. For FGF-19, fasting FGF-19
levels were unchanged after adherence to a low-calorie diet
(800–1100 kcal per day) for 28 days in morbidly obese indi-
viduals [50]. Moreover, 3 weeks’ intervention with a very
low-calorie diet in obese subjects had no significant effect




Record after duplicates removed:
(N=229)
Records excluded on screening
of titles/abstracts: (n=185)
Full text article assessed for 
eligibility: (n=44)
Excluded studies (n= 19)
Assessed postprandial levels of 
outcomes after a meal test: (n=7)
Used a lifestyle weight loss program: 
(n=2)
Study duration was less than 1 month: 
(n=1)
Case control studies: (n=2)
Animal or in vitro studies: (n=3)
Used duodenal–jejunal bypass liner 
device implantation (n=2)
Review: (n=2)
Studies include in the meta-analysis: 
(n= 25) 
Fig. 1 Flow chart of the study
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due to short follow-up duration and thus a negligible weight
loss.
Increased FGF-19 concentrations and a long-term decrease
in FGF-21 following BS observed in this meta-analysis could
directly play a role in some of the positive metabolic changes
of BS in obese patients. Both FGF-19 and FGF-21 have been
shown to be involved in the etiopathology of type 2 diabetes
and obesity, being potential therapeutic targets for the treat-
ment of these metabolic complications [16]. They promote
fatty acid oxidation; improve insulin sensitivity; increase met-
abolic rate; and, at pharmacological doses, induce weight loss
and have hypolipidemic and antidiabetic impacts [52–55].
Studies have documented that FGF-19, as an endocrine hor-
mone, represses cholesterol 7α-hydroxylase (CYP7A1) gene
transcription and thus downregulates the synthesis and secre-
tion of bile acids (BAs) [29]. FGF-19 appears to decrease Lp
(a) production, a highly atherogenic particle [56], hereby re-
ducing coronary artery disease severity [57]. Accordingly, one
of the mechanisms for the remission of diabetes and metabolic
diseases after BS may be mediated by improving FGFs.
It has been confirmed that serum levels of FGF-19 are
reduced in obese patients, while FGF-21 concentrations are
elevated in obesity, being further increased in obesity-related
diabetes [34]. However, the expected beneficial effects of the
paradoxically increase in FGF-21 in obesity are absent, which
proposes that obesity is a FGF-21-resistant state [6]. Reduced
FGF-21 levels ≥ 1 year after BS in our meta-analysis therefore
might propose partial normalization of FGF-21 sensitivity,
yielding a normalization and decrease in its circulating levels.
Nevertheless, it is surprising to identify that FGF-21 level is
elevated after RYGB. Following surgery, FGF-21 resistance
is expected to be reduced quickly [35], and the observed ele-
vation in serum level of FGF-21 after RYGB is to some extent
conflicting to this. Some mechanisms might elucidate that
FGF-21 level is not reverted following RYGB. First, RYGB
can activate liver peroxisome proliferator-activated receptor a
(PPARa) [48], which in turn increase the hepatic production
of FGF-21 [58]. Second, significant alterations in intestinal
hormones following RYGB could modulate FGF-21 concen-
trations [34]. Ultimately, RYGB might totally improve FGF-
21 resistance [16], and a further elevation in FGF-21 concen-
trations may be a mechanism elucidating the better metabolic
outcomes of RYGB over other bariatric surgeries. For in-
stance, elevated FGF-21 concentrations and associated im-
provement in FGF-21 resistance will stimulate mitochondrial
oxidation, thus playing a role in weight loss through a main
pathway [35]. In high-fat diet/streptozotocin-induced diabetic
rats, both duodenal–jejunal bypass and SG improved FGF-21
Fig. 2 Overall and stratified
analysis by surgery type for the
effect of bariatric surgery on the
FGF-19 changes. SG sleeve gas-
trectomy, RYGB Roux-en-Y
gastric bypass. Other: (duodenal
diverted SG with ileal interposi-
tion (DDSG-II), laparoscopic ad-
justable gastric band (LAGB),
laparoscopic greater curvature
plication (LGCP), and various
surgery types)
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Table 2 Subgroup analyses for
the effect of bariatric surgery on
FGF-19 and FGF-21
concentrations
Subgrouped by No. of
data
sets






FGF-19 Type of surgery
RYGB 10 39.09 (20.66–57.53) ˂ 0.001 77.6 ˂ 0.001
SG 14 62.55 (46.07–79.03) ˂ 0.001 41.8 0.07
Other 3 42.42 (− 14.38 to 99.21) 0.14 80.3 0.006
Follow-up period
˂ 1 year 10 29.10 (11.84–46.37) 0.001 85.4 ˂ 0.001
≥ 1 year 17 58.96 (41.64–76.28) ˂ 0.001 65.3 ˂ 0.001
Baseline BMI
˂ 45 20 44.73 (29.08–60.39) ˂ 0.001 75.4 ˂ 0.001
≥ 45 7 52.25 (27.41–77.08) ˂ 0.001 79.6 ˂ 0.001
Sex
Male 1 163.20 (15.42–310.98) 0.03 – –
Female 5 11.55 (− 15.14 to 38.23) 0.39 54.3 0.06




9 55.93 (49.23–62.62) ˂ 0.001 22.4 0.24




5 8.66 (− 3.74 to 21.07) 0.17 13.6 0.32
FGF-21 Type of surgery
RYGB 7 188.84 (6.85–370.83) 0.04 93.9 ˂ 0.001
SG 4 − 78.10 (− 161.65 to 5.44) 0.06 40.9 0.16
Other 3 34.12 (− 128.88 to 197.12) 0.68 87.2 ˂ 0.001
Follow-up period
˂ 1 year 6 288.81 (− 49.78 to 627.41) 0.09 93.1 ˂ 0.001
≥ 1 year 7 − 41.27 (− 70.74 to − 11.81) 0.006 10.8 0.34
Baseline BMI
˂ 45 9 − 18.37 (− 85.53 to 48.80) 0.59 71.2 0.001
≥ 45 4 228.11 (− 114.61 to 570.84) 0.19 96.5 ˂ 0.001
Sex
Female 4 2.46 (− 133.85 to 138.78) 0.97 51.4 0.10




8 92.64 (− 51.66 to 236.94) 0.20 94.0 ˂ 0.001




5 17.57 (− 80.82 to 115.97) 0.72 74.5 0.003
RYGB Roux-en-Y gastric bypass, SG sleeve gastrectomy
a Effect size was expressed as weighted mean difference
b For meta-analysis, p < 0.05 was considered to be a significant effect by using a random-effects model
c The I2 statistic was calculated by using Cochran’s test, and I2 > 50% was considered to indicate significant
heterogeneity across studies
d p value for I2
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sensitivity and restored FGF-21 signaling pathway by increas-
ing the expression of phosphorylated extracellular signal-
regulated kinase 1/2 (ERK1/2) and FGF receptor 1 (FGFR1)
1 year after surgery [59]. Moreover, Fjeldborg et el. [44] re-
vealed that beta-klotho (KLB) and FGF-R1 are upregulated in
adipose tissue in human subjects undergoing RYGB surgery.
FGF-21 rises in metabolic stresses or after a rapid and
massive weight or muscle loss, which mainly occurs during
the first postoperative year after BS [6, 60]. Accordingly, at
short time, FGF-21 should be only considered as a marker of
metabolic stress [6]; nevertheless, we found no significant
change in FGF-21 in studies with follow-up ˂ 1 year. As
FGF-21 concentration is tightly controlled nutritionally, one
of the possible involving factors in reduced serum FGF-21
after a long-term weight loss (≥ 1 year) could be decreased
food intake following BS [45]. This mechanism is supported
by this observation that the FGF-21 levels are significantly
decreased in chronically malnourished individuals with an-
orexia nervosa [16, 61]. On the other side, in subjects with
obesity, the levels of BAs are low [62], but, after RYGB,
serum BAs have been reported to be raised [35]; since FGF-
19 is responsive to BAs, the increased FGF-19 concentrations
might indeed be resulted from the increased levels of BAs
[35]. Moreover, it has been found that, in patients with meta-
bolic diseases, such as nonalcoholic fatty liver disease [63]
and T2DM [64], serum level of FGF-19 is lower, while
FGF-21 is higher in patients with diabetes compared with that
in healthy individuals [65]. When serum concentrations of
FGF-21 were > 500 mg/ml and FGF-19 < 200 mg/ml, 91%
of patients had diabetes, suggesting that FGF-19/FGF-21 se-
rum levels are remarkably dysregulated in T2DM and other
obesity-related metabolic complications [65]. FGF-19 pro-
motes glycogen synthesis and reduces gluconeogenesis,
whereas concurrently decreasing triglyceride and cholesterol
within the liver [66], all showing the clinical importance of
increase in this hormone for the management of lipid and
glycemic control in patients after BS. Thus, changes in the
BAs-FGF-19 axis might involve the favorable metabolic al-
terations after BS. So et al. [67] recently published a meta-
analysis focusing on change in bile acid metabolism following
bariatric surgery and also analyzed 9 studies on FGF-19,
which the results were in line with our finding. It should be
considered that the study by So et al. included only 9 studies
on FGF-19 while we included 19 studies with 27 data sets on
this hormone. Therefore, we strongly believe that the recently
published meta-analysis on FGF-19 has missed many eligible
studies (missed 10 studies and analyzed 9 studies) and is po-
tentially at risk of bias. Moreover, they did not assess changes
in FGF-21 after bariatric surgery, and subgroup analysis for
FGF-19 was not done. We performed analysis by the type of
surgery, follow-up period, baseline BMI, sex, and background
disease of participants and, as novel findings, found that the
pooled effect sizes are significantly affected by these factors.
Presently, our study is the most comprehensive meta-analysis
on FGF-19 and the first meta-analysis on FGF-21.
As a strength point, no evidence for publication bias was
observed. However, this meta-analysis had some limitations.
First, there was a significant heterogeneity across the included
Fig. 3 Overall and stratified
analysis by surgery type for the
effect of bariatric surgery on the
FGF-21 changes. SG sleeve gas-
trectomy, RYGB Roux-en-Y
gastric bypass. Other: (duodenal
diverted SG with ileal interposi-
tion (DDSG-II), laparoscopic ad-
justable gastric band (LAGB),
laparoscopic greater curvature
plication (LGCP), and various
surgery types)
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publications; despite that, we used random-effects method to
consider the heterogeneity. Our subgroup andmeta-regression
analyses found that surgery type, time of follow-up, back-
ground disease, and the sex of participants are potential
sources of heterogeneity, suggesting that differences in these
factors among various articles might partly justify the ob-
served heterogeneity. Second, the included publications were
generally observational case series and, thus, lack controls to
consider any temporal variation in FGFs’ concentrations that
might exist. In fact, because of the severity of BS and its
possible health complications, the majority of the analyzed
articles reported a lack of ethical support from their organiza-
tions for a randomized clinical trial. Finally, however most
studies recruited middle-age participants; one of the analyzed
papers was performed on late adolescents (with a mean age of
17.4 year), and it is possible that the expression of FGFs in this
population be different to that of the others. Nonetheless, we
used the random-effects approach to control for such factors.
Future Directions
In addition to FGF-19 and FGF-21, it is well-known that FGF-
23 has important metabolic roles; nevertheless, studies on the
effects of metabolic surgery on the fibroblast growth factors
have focused on serum FGF-19 and FGF-21. Therefore, future
studies should also evaluate changes in FGF-23 following bar-
iatric surgery. Furthermore, there are some studies on changes
in postprandial peak or AUC in FGF-19 and FGF-21 levels that
significant differences in these hormones may be found after
Fig. 4 Meta-regression analysis
for the effect of bariatric surgery
on FGF-19 (a) and FGF-21 (b)
levels based on follow-up
duration
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BS.Meta-analysis of postprandial peak in FGFs is recommend-
ed for future studies. Given that the included studies were pro-
spective nonrandomized in design and that the quality of evi-
dence for FGF-21 was low, future studies with randomized
clinical trial could yield a more reliable result in this regard.
Moreover, recognizing the molecular underpinnings of BS
has a great significance, as this might reveal new drug targets
for more durable and potent medical treatments. FGF-19 and
FGF-21 could be candidates for such targets. The impacts of
single-hormone therapies have been disappointing occasional-
ly, and thus, some researchers are presently concentrating on
developing a combination therapy of hormones. For instance,
the levels of the gut hormones peptide YY, glucagon-like pep-
tide 1 (GLP-1), and oxyntomodulin all are increased in re-
sponse to RYGB [68] and were recently combined as a subcu-
taneous injectable therapeutic in a clinical trial of obese patients
with T2DM and compared against a very low-calorie diet,
RYGB, and placebo [69]. This combined therapy resulted in
a remarkable improvement in insulin sensitivity, which was
akin to that of RYGB, although the weight loss induced by
the therapeutic was about half that of the RYGB group after
4 weeks of surgery. Considering findings reported herein, it
might be valuable to investigate the effectiveness of a
quadruple-hormone therapy for diabetes and obesity, combin-
ing FGF-19 or FGF-21 with the three previously hormones in
the future studies.
Conclusions
Our pooled analyses provided evidence that significant weight
loss after BS reduces serum levels of FGF-19 but might
Fig. 5 Funnel plot for studies
investigating the effect of bariatric
surgery on FGF-19 (a) and FGF-
21 (b) levels. WMD weighted
mean difference, se (WMD) stan-
dard error for weighted mean
difference
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increase FGF-21 after RYGB or decrease FGF-21 after ≥
1 year of follow-up. Since morbidly obese people are at high
risk for metabolic diseases and these biomarkers are associat-
ed with an improvement in metabolism, the results found in
this meta-analysis could have clinical values for morbidly
obese people undergoing BS.
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